Skip to content

A Prospective Randomized, Multicentre, Parallel Group, Placebo Controlled Trial of Dr SC DEB S Rheumalin in patients with acute and chronic pain in different parts of the human body

A Prospective Randomized, Multicentre, Parallel Group, Placebo Controlled Trial of Dr SC DEB S Rheumalin in patients with acute and chronic pain in different parts of the human body - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/112231
Enrollment
165
Registered
2026-06-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: M255- Pain in joint

Interventions

Intervention1: Dr SC DEB S Rheumalin homoeopathic medicine: Composition: Each 300Mg Contains 1. Bryonia Alba Q 0.003ml 2. Guaiacum Q 0.003ml 3. Macrotinum 2X 0.03 mg 4. Apocynum Cannabunum Q 0.003 ml

Sponsors

DR S C DEB HOMOEO RESEARCH LABORATORY PVT LTD
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18-70 years 2. Both male &female 3. Suffering Acute or Chronic pain 4. Intelligent enough to carefully record the facts, subjective & objective symptom s generated by the drug proving. 5. Able to be informed of the nature of the study and willing to give written informed consent.

Exclusion criteria

Exclusion criteria: 1. Any disease or condition which might compromise the hematotopic, renal, endrocrine, pulmonary, central nervous system. Cardiovascular, immunological, dermatological, or any other body system. 2. Covid 19 RT-PCR positive individuals 3. Persons with colours blindness 4. Person who have undergone surgery in last two months, planed medical/ dental treatment during the proving period including herbal or dietary supplements, procedures or medication that are likely to interfere with or substantially alter responsiveness to the proving subjects. 5. Emotionally disturbed, hysterical, or anxious persons. 6. Persons having known history of allergies, food hypersensitivity, ect. 7. Women during pregnancy. 8. Participations in another clinical or proving trial the last 6 months.

Design outcomes

Primary

MeasureTime frame
Pain relief, Efficacy of the medicine and quality of lifeTimepoint: At Base line and every week, upto 1 month

Secondary

MeasureTime frame
Efficacy of the medicine in pain relief & quality of lifeTimepoint: At Base line & every week, upto 1 month

Countries

India

Contacts

Public ContactDr. Samit Ghosh

DR S C DEB HOMOEO RESEARCH LABORATORY PVT LTD

drsamitghosh@gmail.com8910092118

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026